IL129326A0 - Method for inhibiting stress-activated protein kinases - Google Patents

Method for inhibiting stress-activated protein kinases

Info

Publication number
IL129326A0
IL129326A0 IL12932697A IL12932697A IL129326A0 IL 129326 A0 IL129326 A0 IL 129326A0 IL 12932697 A IL12932697 A IL 12932697A IL 12932697 A IL12932697 A IL 12932697A IL 129326 A0 IL129326 A0 IL 129326A0
Authority
IL
Israel
Prior art keywords
protein kinases
activated protein
inhibiting stress
inhibiting
stress
Prior art date
Application number
IL12932697A
Other languages
English (en)
Original Assignee
Boehringer Mannheim Pharm Corp
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Pharm Corp, Smithkline Beecham Corp filed Critical Boehringer Mannheim Pharm Corp
Publication of IL129326A0 publication Critical patent/IL129326A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL12932697A 1996-10-09 1997-10-09 Method for inhibiting stress-activated protein kinases IL129326A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2845996P 1996-10-09 1996-10-09
PCT/US1997/018272 WO1998015272A1 (en) 1996-10-09 1997-10-09 Method for inhibiting stress-activated protein kinases

Publications (1)

Publication Number Publication Date
IL129326A0 true IL129326A0 (en) 2000-02-17

Family

ID=21843560

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12932697A IL129326A0 (en) 1996-10-09 1997-10-09 Method for inhibiting stress-activated protein kinases

Country Status (16)

Country Link
US (1) US6214854B1 (cs)
EP (1) EP0946172A4 (cs)
JP (1) JP2002512591A (cs)
KR (1) KR20000048967A (cs)
CN (1) CN1157188C (cs)
AU (1) AU4751897A (cs)
BR (1) BR9712283A (cs)
CA (1) CA2267967A1 (cs)
CZ (1) CZ123099A3 (cs)
IL (1) IL129326A0 (cs)
NO (1) NO991655L (cs)
NZ (1) NZ335080A (cs)
PL (1) PL332638A1 (cs)
TR (1) TR199900762T2 (cs)
WO (1) WO1998015272A1 (cs)
ZA (1) ZA979055B (cs)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393488A1 (en) 1999-12-07 2001-06-14 Duke University Use of .alpha.1ar subtype-selective drugs in patients with acute myocardial infarction
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2003231283A1 (en) * 2002-04-30 2003-11-17 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
US7268156B2 (en) * 2002-06-27 2007-09-11 Sb Pharmco Puerto Rico Inc. Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
US20050261355A1 (en) * 2002-06-27 2005-11-24 Sb Pharmco Puerto Rico Inc., Carvedilol hydobromide
JP2007525188A (ja) 2003-05-16 2007-09-06 インターミューン インコーポレイテッド 合成ケモカイン受容体リガンドおよびその使用方法
CN103145715B (zh) 2003-10-14 2016-08-03 F·霍夫曼-罗须公司 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
EP1691789B1 (en) * 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
WO2005051325A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol compositions methods of treatment and delivery
JP2007512372A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
MX2007001589A (es) * 2004-08-09 2007-08-02 Alios Biopharma Inc Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
US12091408B2 (en) * 2013-08-30 2024-09-17 Uti Limited Partnership Store overload-induced calcium release inhibitors and methods for producing and using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5405863A (en) 1992-12-01 1995-04-11 Smithkline Beecham Corporation Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds
US5308862A (en) 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5643915A (en) * 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies

Also Published As

Publication number Publication date
EP0946172A1 (en) 1999-10-06
NZ335080A (en) 2000-04-28
ZA979055B (en) 1999-05-10
CN1157188C (zh) 2004-07-14
WO1998015272A8 (en) 2000-03-23
NO991655D0 (no) 1999-04-08
BR9712283A (pt) 1999-08-31
US6214854B1 (en) 2001-04-10
CN1239888A (zh) 1999-12-29
TR199900762T2 (xx) 1999-07-21
CZ123099A3 (cs) 1999-11-17
KR20000048967A (ko) 2000-07-25
NO991655L (no) 1999-06-08
WO1998015272A1 (en) 1998-04-16
JP2002512591A (ja) 2002-04-23
AU4751897A (en) 1998-05-05
EP0946172A4 (en) 2002-05-22
PL332638A1 (en) 1999-09-27
CA2267967A1 (en) 1998-04-16

Similar Documents

Publication Publication Date Title
PL330120A1 (en) Farnesilic protein transferase inhibitors
PL331338A1 (en) Thiosulphonamidic metaloprotease inhibitors
IL125829A0 (en) Method of sharing cryptokey
IL127416A0 (en) Method for enhancing gene transfer
IL118196A0 (en) Methods for inhibiting bone loss
ZA98643B (en) Method for inhibiting the growth of cancers
PL331803A1 (en) Bidonoric metaloprotease inhibitors
GB2345063B (en) Method
ZA979055B (en) Method for inhibiting stress-activated protein kinases
HUP9903570A3 (en) Acylation method for an aromatic compounds
ZA974265B (en) Method for preservation
IL131000A0 (en) Method for preparing oxy-diphthalic anhydrides
GB9700320D0 (en) Method
GB9423258D0 (en) Method for range determination
GB2298252B (en) Procedure for gearbox-type determination
GB9619758D0 (en) Method
GB9605709D0 (en) Method
GB9718041D0 (en) Method for making surfboard
GB9624822D0 (en) Method
GB9716920D0 (en) Method for making surfboard
AU9526298A (en) Method for inhibiting eukaryotic protein kinases
IL120327A0 (en) Improved bore for weapons
HK1025038A (en) Method for inhibiting stress-activated protein kinases
EP0926499A4 (en) METHOD TO PREVENT LACTOFERRINE ADSORPTION
GB9605482D0 (en) Method